Registration - In-house Corporation

Pfizer Canada ULC / Najah Sampson, President

Registration Information

In-house Corporation name: Pfizer Canada ULC
Responsible Officer Name: Najah Sampson, President
Responsible Officer Change History
Initial registration start date: 2007-04-27
Registration status: Active
Registration Number: 951977-15283

Associated Communications

Total Number of Communication Reports: 328

Monthly communication reports in the last 6 months: 0

Version 32 of 41 (2021-09-15 to 2021-12-01)

Registration versions:

Version 32 of 41 (2021-09-15 to 2021-12-01)

Lobbying Information

Subject Matters

Consumer Issues
Economic Development
Government Procurement
Health
Industry
Intellectual Property
International Relations
International Trade
Labour
Regional Development
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Discussions on the procurement of a COVID19 vaccine candidate

Grant, Contribution or Other Financial Benefit, Policies or Program

Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver

Legislative Proposal, Bill or Resolution, Regulation

Monitoring and engaging on the Act respecting certain measures in response to COVID-19 and the changes to the Patent Act, including eventual regulations and guidelines, formally known as Bill C-13, An Act respecting certain measures in response to COVID-19 .

Policies or Program

Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages and discussion on COVID19 potential impacts
Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for high-cost drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing strategy
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED).
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

Policies or Program, Regulation

Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Atlantic Canada Opportunities Agency (ACOA)
Canada Border Services Agency (CBSA)
Canada Economic Development for Quebec Regions
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Employment and Social Development Canada (ESDC)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Intergovernmental Affairs Secretariat (IGA)
Justice Canada (JC)
National Defence (DND)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)
Senate of Canada
Transport Canada (TC)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)
Western Economic Diversification Canada (WD)

Government institutions added through a monthly communication report

Immigration, Refugees and Citizenship Canada (IRCC)

In-house Corporation Details

Description of activities

Pfizer's mission is to discover and develop innovative medicines, vaccines and other products to improve the quality of life of people and animals.

Responsible officer name and position during the period of this registration

Cole C. Pinnow, President

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada

Telephone number: 514-693-4264

Parent Company Information

PFIZER INC
- 235 EAST 42ND STREET
  NEW YORK, NY 10017-5755
  United States of America

Subsidiary Beneficiary Information

Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Jonathan Cullen, Vice-President, Legal Affairs & General Counsel | No public offices held
Frédéric Lavoie, Vice-président, Remboursement et relations gouvernementales | No public offices held
Fabien Paquette, Vaccines Canada Lead | No public offices held
Cole C. Pinnow, President | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Steven Hogue, Director, Federal & Industry Relations | Public offices held

Pfizer Canada ULC

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Pfizer Canada ULC	2009-05-13	current

The following names have been used before July 2, 2008

Pfizer Canada ULC

Pfizer Canada ULC

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Najah Sampson	2022-05-16	Current
Cole C. Pinnow	2020-01-06	2022-05-16
John Helou	2012-01-30	2020-01-06
Paul Lévesque	2007-04-27	2012-01-30

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Deputy Director of Communications Office of the Prime Minister of Canada, Communications	November 2002 to December 2003	Not a designated office
Special Assistant (Quebec Issues) Office of the Prime Minister of Canada, Operations	July 2001 to November 2002	Not a designated office
Special Assistant (Quebec and Atlantic Issues) Department of Fisheries & Oceans, Minister's Office	August 1999 to July 2001	Not a designated office
Special Assistant (Quebec and Atlantic Issues) Canada Customs and Revenue Agency, Minister's Office	September 1998 to August 1999	Not a designated office

Date Modified:: 2025-03-12

Search and menus

Language selection

Registration - In-house Corporation

Pfizer Canada ULC / Najah Sampson, President

Registration Information

Associated Communications

Version 32 of 41 (2021-09-15 to 2021-12-01)

Version 32 of 41 (2021-09-15 to 2021-12-01)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Grant, Contribution or Other Financial Benefit, Policies or Program

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Policies or Program, Regulation

Communication Techniques

Government Institutions

Government institutions added through a monthly communication report

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties